Impact of anti-PEG IgM antibodies on the pharmacokinetics of pegylated asparaginase preparations in mice.
- Sabine Poppenborg, J. Wittmann, F. Leenders
- BiologyEuropean Journal of Pharmaceutical Sciences
- 25 August 2016
Comparative pharmacokinetic/pharmacodynamic characterisation of a new pegylated recombinant E. colil-asparaginase preparation (MC0609) in Beagle dog
- S. Borghorst, G. Hempel, Sabine Poppenborg, D. Franke, T. König, J. Baumgart
- Biology, MedicineCancer Chemotherapy and Pharmacology
- 17 June 2014
The new pegylated recombinant l-asparaginase preparation MC0609 revealed striking differences in PK/PD properties compared with Oncaspar® in rat and dog.